Shows & Panels
- Accelerate and Streamline for Better Customer Service
- Ask the CIO
- The Big Data Dilemma
- Carrying On with Continuity of Operations
- Client Virtualization Solutions
- Data Protection in a Virtual World
- Expert Voices
- Federal Executive Forum
- Federal IT Challenge
- Federal Tech Talk
- Feds in the Cloud
- Health IT: A Policy Change Agent
- Improving Healthcare Outcomes through IT Policy
- IT Innovation in the New Era of Government
- Making Dollars And Sense Out of Data Center Consolidation
- Navigating the Private Cloud
- One Step to the Cloud, Two Steps Toward Innovation
- Path to FDCCI Compliance
- Take Command of Your Mobility Initiative
Shows & Panels
Ameridose in Mass. to remain closed through year
Friday - 11/16/2012, 8:23pm EST
BOSTON (AP) - A Massachusetts drug company with the same founders as a compounding pharmacy tied to a deadly meningitis outbreak has agreed with state regulators to remain closed through the year.
Ameridose first agreed to close for inspection in October after tainted steroids from its sister company, the New England Compounding Center, were linked to a fungal meningitis outbreak that caused 32 deaths. The agreement has been extended several times. The latest would have expired Monday.
Ameridose has laid off most workers and recalled its products, though none has been found contaminated. The company makes injectable drugs for hospitals.
The U.S. Food and Drug Administration said Monday that its monthlong inspection of Ameridose found potential sources of contamination, including leaky ceilings and insects. Ameridose has said it'll work to address those issues.
(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)